460 related articles for article (PubMed ID: 35073561)
41. The association of Epstein-Barr virus infection with CXCR3
van Langelaar J; Wierenga-Wolf AF; Samijn JPA; Luijks CJM; Siepman TA; van Doorn PA; Bell A; van Zelm MC; Smolders J; van Luijn MM
Eur J Immunol; 2021 Mar; 51(3):626-633. PubMed ID: 33152118
[TBL] [Abstract][Full Text] [Related]
42. EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
Erdur H; Scholz V; Streitz M; Hammer M; Meisel C; Schönemann C; Wandinger KP; Rosche B
J Neuroimmunol; 2016 May; 294():14-7. PubMed ID: 27138093
[TBL] [Abstract][Full Text] [Related]
43. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.
Serafini B; Severa M; Columba-Cabezas S; Rosicarelli B; Veroni C; Chiappetta G; Magliozzi R; Reynolds R; Coccia EM; Aloisi F
J Neuropathol Exp Neurol; 2010 Jul; 69(7):677-93. PubMed ID: 20535037
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
45. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
46. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
[TBL] [Abstract][Full Text] [Related]
47. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
[TBL] [Abstract][Full Text] [Related]
48. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells.
Lossius A; Johansen JN; Vartdal F; Robins H; Jūratė Šaltytė B; Holmøy T; Olweus J
Eur J Immunol; 2014 Nov; 44(11):3439-52. PubMed ID: 25103993
[TBL] [Abstract][Full Text] [Related]
49. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
Pender MP; Csurhes PA; Lenarczyk A; Pfluger CM; Burrows SR
J Neurol Neurosurg Psychiatry; 2009 May; 80(5):498-505. PubMed ID: 19015225
[TBL] [Abstract][Full Text] [Related]
50. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
51. Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait.
Al-Temaimi R; Alroughani R; Jacob S; Al-Mulla F
J Neuroimmunol; 2015 Aug; 285():57-61. PubMed ID: 26198919
[TBL] [Abstract][Full Text] [Related]
52. Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
Kyllesbech C; Trier N; Slibinskas R; Ciplys E; Tsakiri A; Frederiksen JL; Houen G
J Neuroimmunol; 2022 Jun; 367():577868. PubMed ID: 35477126
[TBL] [Abstract][Full Text] [Related]
53. Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus.
Westhoff Smith D; Sugden B
Viruses; 2013 Jan; 5(1):226-40. PubMed ID: 23325328
[TBL] [Abstract][Full Text] [Related]
54. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.
Lu J; Murakami M; Verma SC; Cai Q; Haldar S; Kaul R; Wasik MA; Middeldorp J; Robertson ES
Virology; 2011 Feb; 410(1):64-75. PubMed ID: 21093004
[TBL] [Abstract][Full Text] [Related]
55. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
56. Epstein-Barr virus and multiple sclerosis.
Soldan SS; Lieberman PM
Nat Rev Microbiol; 2023 Jan; 21(1):51-64. PubMed ID: 35931816
[TBL] [Abstract][Full Text] [Related]
57. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
58. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
59. Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris.
Wang M; Jiang S; Liu X; Wang Y
Appl Microbiol Biotechnol; 2013 Jul; 97(14):6251-62. PubMed ID: 23685476
[TBL] [Abstract][Full Text] [Related]
60. Mimicking the brain: Epstein-Barr virus and foreign agents as drivers of neuroimmune attack in multiple sclerosis.
Thomas OG; Olsson T
Front Immunol; 2023; 14():1304281. PubMed ID: 38022632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
